Structural and Compound ALK Resistance Mutations: A Unified Framework to Understand Lorlatinib Failure and Beyond

Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) have dramatically transformed the clinical management of ALK-rearranged non-small cell lung cancer (NSCLC). Successive generations of ALK inhibitors have been developed to overcome resistance mediated by kinase domain mutations, culm...

Полное описание

Библиографические подробности

Главный автор:	Keigo Kobayashi
Формат:	Artigo
Язык:	Inglês
Опубликовано:	MDPI AG 2026-06-01
Серии:	Journal of Respiration
Предметы:	ALK-rearranged NSCLC ALK tyrosine kinase inhibitors compound ALK mutations lorlatinib resistance structure-agnostic strategies tumor evolution
Online-ссылка:	https://www.mdpi.com/2673-527X/6/2/11
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!